These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 19461179

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H, Tsuboi K, Honda I, Kato N, Okochi O, Kobayashi D, Hattori M.
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
    Yoshida Y, Hasegawa J, Nishimura J, Hirota M, Kim Y, Nezu R.
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
    Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, Nomura A, Miyamoto S, Kitano T, Ishiguro H, Yanagihara K, Teramukai S, Sakai Y, Chiba T, Fukushima M.
    Chemotherapy; 2008 Aug; 54(5):395-403. PubMed ID: 18781065
    [Abstract] [Full Text] [Related]

  • 7. [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
    Ishiguro T, Ishibashi K, Okada N, Kuwabara K, Miyazaki T, Yokoyama M, Matsuki M, Sano M, Inoue N, Ishida H.
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2286-8. PubMed ID: 19106598
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].
    Kuboki Y, Ichimura T, Ogura M, Matsuda M, Suenaga M, Shinozaki E, Matsuzaka S, Chin K, Mizunuma N, Hatake K.
    Gan To Kagaku Ryoho; 2008 May; 35(5):781-5. PubMed ID: 18487913
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy].
    Okada N, Ishibashi K, Kuwabara K, Ishiguro T, Hatano S, Hokama N, Tajima Y, Ishii M, Kubota S, Chika N, Miyazaki T, Ishida H.
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):1985-7. PubMed ID: 20037299
    [Abstract] [Full Text] [Related]

  • 15. [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
    Kato T, Matsunaga Y, Motokawa S, Nakagaki S, Nagata N, Yoshida T, Muramatsu T, Kimura H, Ohashi Y, Kudou Y, Shino M, Yamazaki K, Boku N.
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1697-702. PubMed ID: 19838030
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [Abstract] [Full Text] [Related]

  • 18. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L.
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
    Jensen SA, Sørensen JB.
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):57-64. PubMed ID: 21603868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.